- Targeting unmet medical needs with proprietary topical formulations
- License-based business model translates to worldwide opportunities
- Patented Invisicare™ technology offers enhanced drug delivery system
- Global skincare market projected to reach $135 billion by 2021
Research and development company Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI), continues to add significant value to its core business model with several key movements involving a proposed merger, new licensing agreements and formation of a specialized subsidiary.
The Company’s November 27 announcement that it has entered into a non-binding term sheet regarding a proposed merger with Quoin Pharmaceuticals Ltd., pending customary closing conditions, melds industry veterans committed to developing products which address major societal issues with Skinvisible’s team of R&D scientists. Quoin’s two lead products are targeting crises such as the opioid epidemic and the military veteran suicide rate that result in the death of almost 120 people in the United States every day (http://cnw.fm/b0YgF).
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer